Reporter Zhang Min from this newspaper
On February 28th, the reporter learned from BeiGene that the US Food and Drug Administration (FDA) has accepted the company's biological product license application (BLA) for tirizumab, which is used in combination with fluoropyrimidine and platinum chemotherapy to treat locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma patients. The FDA is expected to make a decision on the BLA in December 2024.
In the past 20 years, China's innovative pharmaceutical industry has entered a fast lane of development, accelerating the formation of "new quality productive forces", from the focus on imitation to the frequent implementation of national policies encouraging pharmaceutical innovation, and then to pharmaceutical companies taking bold steps to "go global". In 2023, China approved the listing of 40 innovative drugs, and multiple innovative drugs successfully crossed European and American levels. The scale of authorized cooperation with foreign countries reached a new high, and innovative drug companies on the Science and Technology Innovation Board ushered in a "fruitful year".
Recently, the Shanghai Stock Exchange held a New Quality Productivity Industry Salon on the Science and Technology Innovation Board to deeply explore the opportunities and challenges for the development of China's innovative pharmaceutical industry, and the industry has a strong momentum of development. As an advanced enterprise among pharmaceutical companies listed on the Science and Technology Innovation Board, in 2023, BeiGene achieved remarkable results in multiple aspects such as globalization, commercialization, and research and development innovation with its core products.
According to the performance report, in 2023, BeiGene's product revenue was 15.504 billion yuan, compared to 8.48 billion yuan in the same period last year, a year-on-year increase of 82.8%. BeiGene's sales of Terezumab totaled 3.806 billion yuan last year, compared to 2.859 billion yuan in the same period last year, a year-on-year increase of 33.1%; The global sales of Zebutinib, independently developed by the company, totaled 9.138 billion yuan, becoming the first milestone in China to exceed one billion US dollars and officially entering the ranks of "heavyweight bombs" drugs.